Home

Our vision is to be the global leader in prescription cannabinoid medicines, developing and providing pharmaceutical products which address clear unmet needs.

Justin Gover
Chief Executive Officer

Recent News

Dec 01, 2017
At the AES Annual Meeting 2017 in Washington, DC, Greenwich Biosciences will continue its commitment to advance cannabinoid science by sponsoring several events and posters, including:
Jun 22, 2017
On June 23rd, we will join individuals and advocacy organizations across the globe as they participate in events to increase awareness about Dravet syndrome, a rare, severe form of childhood-onset epilepsy.

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epilepsy

CBD Oral Solution
Dravet Syndrome
2 Phase 3 Trials
Completed Phase 3
CBD Oral Solution
Lennox-Gastaut Syndrome
Completed Phase 3
CBD Oral Solution
Tuberous Sclerosis Complex
Phase 3 Trial Recruiting
Completed Phase 2
CBD Oral Solution
Infantile Spasms
Phase 2 Trial Underway
Phase 2
CBD IV
Neonatal Hypoxic-ischemic Encephalopathy
Pre-Clinic